Close Menu

MDxHealth

The company said the revenue increase was driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.

The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.

ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns.

The deal marks the latest in a series of distribution agreements MDxHealth has recently signed for the SelectMDx test.

The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.

The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.

The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.

Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.

The European Health Centre Innovation will now distribute SelectMDx and ConfirmMDx to its urology customers throughout the country.

The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.